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New Model for Estimating Glomerular Filtration Rate in
Patients With Cancer
Tobias Janowitz, Edward H. Williams, Andrea Marshall, Nicola Ainsworth, Peter B. Thomas, Stephen J. Sammut,
Scott Shepherd, Jeff White, Patrick B. Mark, Andy G. Lynch, Duncan I. Jodrell, Simon Tavare´, and Helena Earl
A B S T R A C T
Purpose
The glomerular ﬁltration rate (GFR) is essential for carboplatin chemotherapy dosing; however, the
bestmethod to estimate GFR in patients with cancer is unknown.We identify themost accurate and
least biased method.
Methods
We obtained data on age, sex, height, weight, serum creatinine concentrations, and results for GFR
from chromium-51 (51Cr) EDTA excretionmeasurements (51Cr-EDTA GFR) fromwhite patients$ 18
years of age with histologically conﬁrmed cancer diagnoses at the Cambridge University Hospital
NHS Trust, United Kingdom.We developed a newmultivariable linearmodel for GFR using statistical
regression analysis. 51Cr-EDTA GFR was compared with the estimated GFR (eGFR) from seven
published models and our new model, using the statistics root-mean-squared-error (RMSE) and
median residual and on an internal and external validation data set. We performed a comparison of
carboplatin dosing accuracy on the basis of an absolute percentage error . 20%.
Results
Between August 2006 and January 2013, data from 2,471 patients were obtained. The new model
improved the eGFR accuracy (RMSE, 15.00mL/min; 95%CI, 14.12 to 16.00mL/min) comparedwith
all published models. Body surface area (BSA)–adjusted chronic kidney disease epidemiology (CKD-
EPI) was the most accurate published model for eGFR (RMSE, 16.30 mL/min; 95% CI, 15.34 to
17.38 mL/min) for the internal validation set. Importantly, the new model reduced the fraction of
patients with a carboplatin dose absolute percentage error. 20% to 14.17% in contrast to 18.62%
for the BSA-adjusted CKD-EPI and 25.51% for the Cockcroft-Gault formula. The results were ex-
ternally validated.
Conclusion
In a large data set from patients with cancer, BSA-adjusted CKD-EPI is the most accurate published
model to predict GFR. The newmodel improves this estimation and may present a new standard of
care.
J Clin Oncol 35:2798-2805. © 2017 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
The glomerular ﬁltration rate (GFR), the ﬂuid
volume ﬁltered from the capillaries of the renal
glomeruli into the Bowman’s capsule per unit
time, is used for calculations of carboplatin
chemotherapy doses.1 A number of direct GFR
measurements exist, such as the calculation
on the basis of clearance of chromium-51
EDTA (51Cr-EDTA).2 These methods are costly
and require time and expertise. As a substitute,
models for GFR estimation have been developed
on the basis of readily available data, such as
serum creatinine concentrations, age, and sex of
the patient.3-11
These published models for GFR have been
mainly developed for noncancer patient pop-
ulations that are frequently enriched for patients
with chronic kidney disease. Their usefulness in
patients with cancer has been examined using
only small data sets, and limitations have been
documented.12-16
Uncertainties regarding GFR estimation for
patients with cancer represent an area of clinical
need. Carboplatin chemotherapy doses calculated
using GFR1 are administered to patients with
seminoma, lung, breast, and ovarian cancer, in
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both adjuvant and palliative settings, where accurate dosing is
critical to both outcome and toxicity.17-27 In addition, GFR mea-
surements guide clinicians with regard to cisplatin use, which is
nephrotoxic28,29 and considered with caution in patients with
reduced renal function.30-32 We used the largest published on-
cology data set to identify the most accurate published model as
well as to develop a new model to estimate GFR.
METHODS
Detailed methods and a comprehensive description of development of the
new model are provided in the Data Supplement.
Study Profile and Data Set
The study proﬁle is displayed schematically in Figure 1. The full data
set was compiled at the Cambridge University Hospital NHS Trust, United
Kingdom, from white patients $ 18 years of age with histologically
conﬁrmed cancer diagnoses and a serum creatinine measurement within
30 days of the 51Cr-EDTAGFR–measurement (51Cr-EDTAGFR). The data
set was randomly split at a ratio of 4:1 for model development and internal
model validation. An external validation data set of male patients (n = 111)
with stage I seminoma was obtained from the Beatson West of Scotland
Cancer Centre, Glasgow, United Kingdom. No patient-identiﬁable data
were used. Anonymized data included age, sex, height, weight, serum
creatinine concentration, and results for the accurate GFR value from
51Cr-EDTAGFR. Body surface area (BSA) was calculated using the Du Bois
equation.33 Height, weight, and 51Cr-EDTA GFR were measured on the
same day.
Assessment of Published Models
We compared the 51Cr-EDTA GFR with the GFR estimated using the
following ﬁve published models, with and without BSA adjustment:
Martin, Wright, Mayo, Modiﬁcation of Diet in Renal Disease (MDRD),
and chronic kidney disease epidemiology (CKD-EPI). The Cockcroft-
Gault and the Jelliffe models, which estimate creatinine clearance (ie, an
approximation of GFR), were also assessed.3-10
We used the Calvert equation1 to compare the accuracy of a carbo-
platin dose with an area under the curve (AUC) of 5 mg/mL/min (AUC5)
calculated from 51Cr-EDTA GFR with eGFR for all models.
Model Generation
In brief, we developed a linear model for the relationship between
GFR and the predicting variables. The Box-Cox method34 gave a suitable
transformation to approximate normality. The model variables were
Enrolled in full data set (N = 2,471)
eGFR and carboplatin dosing
compared between seven
published models
Full data set randomly split
Internal validation (n = 494)Model development (n = 1,977)
Data transformations
Stepwise selection of variables
Assessed robustness of new model
by sampling 100 different
development data sets
Fit new model using full data set
eGFR and carboplatin dosing
compared between seven
published models and new model
using external validation data set
External
validation
(n = 111)
eGFR and carboplatin dosing
compared between seven
published models and new model
New model
Fig 1. Schematic representation of study workﬂow.
eGFR, estimated glomerular ﬁltration rate.
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chosen using minimization of a ﬁve-fold cross validation, a leave-one-out
cross validation, and the Bayesian information criterion in a stepwise
method starting from a model containing only an intercept term (null
model).35-40 To address the random component associated with this se-
lection process for the ﬁve-fold cross-validation criterion, 2,000 repetitions
of the process were performed and the most frequent model was taken
forward.
Laboratory Methods and GFR Calculation
GFR was calculated from the measurement of 51Cr-EDTA in three
plasma samples taken over time after intravenous injection of 2 mega-
becquerel (MBq) of 51Cr-EDTA. Serum creatinine (Cre) was measured
using the kinetic Jaffe method.
Statistics
Median percentage error (PE), root-mean-squared error (RMSE),
interquartile range (IQR) of the residuals, and median absolute percentage
error (APE) were used to assess the accuracy of each GFR model for
predicting measured 51Cr-EDTA GFR. A median APE . 20% was con-
sidered a clinically relevant deviation of the carboplatin dose. RMSE results
are expressed with a 95% CI calculated using the x2 distribution. All
median statistics are reported with IQRs.
RESULTS
Between August 2006 and January 2013, data from 2,471 patients
were obtained. The data set was divided randomly into data from
1,977 patients (80%) for model development and from 494 pa-
tients (20%) for internal validation of the new model. The patient
characteristics were similar between the different data sets and are
summarized in Table 1. Serum creatinine and 51Cr-EDTA GFR
were measured within 30 days (median, 6 days; IQR, 2 to 9 days).
The median for 51Cr-EDTA GFR was 81 mL/min (IQR, 63 to
103 mL/min), indicating that most patients had near-normal
kidney function.41 The external validation data set consisted of
patients with stage I seminoma (n = 111), who had a median age
of 39 years (IQR, 33 to 46 years) and a median 51Cr-EDTA GFR of
113 mL/min (IQR, 101 to 131 mL/min; Table 1).
We used the full data set to compare the performance of
seven published candidate models and BSA-adjusted models
(Mayo, Jelliffe, MDRD, and CKD-EPI). For estimating GFR,
CKD-EPI was the most accurate model, with the lowest RMSE at
21.17 mL/min (95% CI, 20.60 to 21.78 mL/min). BSA ad-
justment improved accuracy for the CKD-EPI, MDRD, and
Jelliffe models. After BSA adjustment, CKD-EPI had the lowest
RMSE (16.63 mL/min; 95% CI, 16.18 to 17.10 mL/min), was
least biased (median residual, 0.54 mL/min; IQR, 210.18
to 9.16 mL/min), and had a median PE closest to zero (20.78%;
IQR, 214.09% to 11.19%), the smallest residual IQR (19.34
mL/min), and the smallest median APE (12.33%; IQR, 5.77% to
21.62%).
With regard to carboplatin doses, calculated by the
Calvert equation: dose [mg] = Target AUC [mg/mL/min] 3
(GFR [mL/min] + 25 [mL/min]),1 where dose is linearly
related to GFR, the statistics of RMSE, median residual, and
IQR of residuals are direct reﬂections of the GFR results but
median PE and median APE are different. We determined the
fraction of patients receiving doses with a clinically relevant
APE . 20%, which was smallest for BSA-adjusted CKD-EPI
(17.38%). BSA-adjusted CKD-EPI, therefore, was the best-
performing published model for estimation of GFR and
calculation of carboplatin dose in our data set from patients
with cancer (Data Supplement).
Next, we investigated if our large data set could be used to
develop a new and better model. We ﬁrst noticed that the un-
transformed GFR data were not normally distributed (Data
Supplement). The Box-Cox method suggested that modeling the
square root of GFR would satisfy the assumptions of a linear model
(Data Supplement). The relationship between square root GFR and
untransformed creatinine was not linear (Data Supplement). Of
several tested data transformations, natural logarithmic trans-
formation (ln) achieved the best linearity between GFR and the
transformed creatinine (Data Supplement). However, graphical
analysis of the residual against transformed serum creatinine
concentration for a simple model (ie, a model that had the var-
iables ln(Cre), sex, and BSA) showed that further transformations
Table 1. Patient Characteristics
Characteristic Full Data Set Development Internal Validation External Validation
No. of patients 2,471 1,977 494 111
Age, years* 61 (50-69), 18-92 61 (50-69), 18-92 63 (51-70), 18-89 39 (33-46), 21-69
Weight, kg* 73 (62-85), 37-163 74 (63-86), 37-149 73 (62-84), 42-163 86 (76-98), 51-161
Height, cm* 168 (161-176), 125-200 168 (161-176), 125-200 168 (160-175), 146-196 178 (174-182), 131-192
BSA, m2* 1.84 (1.67-2.00), 1.24-2.79 1.84 (1.67-2.00), 1.24-2.67 1.83 (1.67-1.99), 1.31-2.79 2.04 (1.92-2.15), 1.48-2.73
Serum creatinine, mg/dL* 0.91 (0.77-1.07), 0.29-5.62 0.91 (0.77-1.07), 0.38-4.05 0.91 (0.77-1.08), 0.29-5.62 0.92 (0.81-1.01), 0.62-1.45
51Cr-EDTA GFR, mL/min* 81 (63-103), 11-211 82 (64-103), 13-211 80 (62-103), 11-187 113 (101-131), 45-202
51Cr-EDTA GFR subgroup†
, 40 mL/min 117 (5) 86 (4) 31 (6) 0 (0)
40-60 mL/min 422 (17) 336 (17) 86 (17) 2 (2)
. 60 mL/min 1,932 (78) 1,555 (79) 377 (76) 109 (98)
Sex†
Female 1,398 (57) 1,114 (56) 284 (57) 0 (0)
Male 1,073 (43) 863 (44) 210 (43) 111 (100)
Abbreviations: BSA, body surface area; 51Cr, chromium-51; GFR, glomerular ﬁltration rate; IQR, interquartile range.
*Data presented as median (IQR), range.
†Data presented as No. (%).
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were required (Data Supplement). Including a quadratic and cubic
term further improved the linearity, better modeled the complex
relationship (Data Supplement), and signiﬁcantly improved
the model (P , .001, F-test). Age, BSA, height, and weight had
an approximately linear relationship with square root GFR (Data
Supplement).
For model selection on the development data set, we used the
leave-one-out, ﬁve-fold, and Bayesian information criteria. All
three of our criteria selected the same model (Eq 1). The ﬁve-fold
criterion selected the model 854 times out of the 2,000 repetitions.
Using the internal validation data set, we compared the
performance of the new model with the performance of the
published models. Bland-Altman and residual plots indicated
that the new model is more accurate, less biased, and less
heteroscedastic, ie, it has more constant variance in different
subpopulations (Fig 2 and Data Supplement). These plots also
demonstrate that the new model, CKD-EPI, and BSA-adjusted
CKD-EPI are least prone to overﬁtting. The new model was the
most accurate and second least biased model for estimating GFR
(Fig 3A and C, Data Supplement). It has the lowest RMSE at
15.00 mL/min (95% CI, 14.12 to 16.00 mL/min) and a median
residual of 0.51 mL/min (IQR, 27.99 to 9.67 mL/min). For the
BSA-adjusted CKD-EPI model, the RMSE and the median re-
sidual were 16.30 mL/min (95% CI, 15.34 to 17.38 mL/min)
and20.03 mL/min (IQR,29.92 to 10.13 mL/min), respectively,
and for the Cockcroft-Gault model, the RMSE and the median
residual were 23.75 mL/min (95% CI, 22.36 to 25.33 mL/min)
and20.79 mL/min (IQR,214.93 to 9.54 mL/min), respectively
(Fig 3C).
We consider use of the new model for calculation of car-
boplatin dosing for patients with cancer to be the most important
area of potential clinical application. Thus we investigated the
fraction of patients who would have received an AUC5 carboplatin
dose that deviated . 20% from the accurate dose calculated using
51Cr-EDTA GFR. This fraction was smallest for the new model,
with an APE. 20% of 14.17% in contrast to 18.62% for the BSA-
adjusted CKD-EPI and 25.51% for the Cockcroft-Gault model (Fig
3D and Data Supplement).
We also investigated utility of the new model to guide pre-
scription of cisplatin, which is an important chemotherapeutic
agent but causes nephrotoxicity.28,29 Of the 58 patients within the
internal validation data set who had ameasured GFR, 50mL/min
(a value that warrants caution for full-dose cisplatin administra-
tion),30-32 the new model returned an eGFR lower than this value
for 31 (53%) patients. This compares with 36 (62%) and 35 (60%)
of patients when the BSA-adjusted CKD-EPI or the Cockcroft-
Gault model was used, respectively. In turn, of the 436 patients who
had a measured GFR. 50 mL/min, a total of nine patients (2.1%,
new model), 16 patients (3.7%, BSA-adjusted CKD-EPI model),
and 29 patients (6.7%, Cockcroft-Gault model) had an eGFR ,
50 mL/min.
This demonstrates limitations of point estimates. However,
the new model satisﬁes all linear modeling assumptions; therefore,
predictive CIs for future unobserved GFR values can be estimated
(Fig 4). For 54 (93%) of the 58 patients with a measured GFR, 50
mL/min, the 95% predictive CI includes 50 mL/min. This in-
creased detection rate of at-risk patients is offset by predictive CIs
that contain 50 mL/min for 158 (36%) patients with a measured
GFR . 50 mL/min.
To assess robustness of the model, the variable selection
process was repeated for the three criteria on 100 different random
partitions of the full data set into development and validation data
sets. The new model remained most frequently returned and has
the form
New model
−100
0
100
Adj CKD−EPI CKD−EPI Mayo
Adj Jelliffe
−100
0
100
Adj MDRD Wright Adj Mayo
Cockcroft Gault
−100
0
100
0 50 100 150 200
MDRD
0 50 100 150 200
Martin
0 50 100 150 200
Jelliffe
0 50 100 150 200
Mean of eGFR and mGFR [mL/min]
m
GF
R 
− 
eG
FR
 [m
L/
m
in
]
Fig 2. Bland-Altman plots of estimated
GFR (eGFR) and measured GFR (mGFR) for
the new model and each of the published
models. The mean of mGFR and eGFR was
plotted against the difference of the two
for the internal validation data set. Posi-
tive differences indicate underestimation
and negative differences indicate over-
estimation. The plots are ordered in as-
cending order of root-mean-squared error
of eGFR from top left to bottom right. The
solid line on each plot represents the mean
of the difference and the dashed lines
are drawn at the mean 6 1.96 times the
standard deviation of the difference. Points
are colored by sex (blue, female; gold, male).
Adj, adjusted; CKD-EPI, chronic kidney dis-
ease epidemiology; MDRD, Modiﬁcation of
Diet in Renal Disease.
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Equation 1:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
GFR
p ¼ b0 þ b1Ageþ b2BSAþ b3lnðCreÞ þ b4lnðCreÞ2 þ b5lnðCreÞ3
þðb6 þ b7AgeÞfif Sex ¼ Mg þ b8Age3BSAþ «
where the errors « are independent, mean zero normally dis-
tributed random variables with a constant variance s2. To get the
most accurate values, the ﬁnal coefﬁcients b0, …, b8 were de-
termined by ﬁtting the model using the full data set (Table 2).
Diagnostic plots for the new model conﬁrmed that no single
data point was inﬂuential in the full data set (highest Cook’s
distance value, 0.094; Data Supplement). Importantly, there was
still no heteroscedasticity in the ﬁnal linear model; thus we
conﬁrmed that calculation of CIs (prediction intervals) for the
eGFR values were appropriate (Data Supplement).
Finally, we externally validated the model using a data set from
a different cancer center. GFR estimation (Data Supplement) and
dose accuracy assessment for carboplatin demonstrated that the
new model remained the most accurate compared with all other
models. The RMSE for the GFR calculated with the new model was
18.94 mL/min compared with 21.33 mL/min for the BSA-adjusted
CKD-EPI and 32.32 mL/min for the Cockcroft-Gault model (Fig
3B and C and Data Supplement). The carboplatin AUC5 APE .
20% was 11.71% for the new model and 18.92% for the BSA-
adjusted CKD-EPI model, which was the next best model (Fig 3D
and Data Supplement). Of the 111 patients in the external vali-
dation data set, 105 (94.6%) had a measured GFR within the 95%
CI (Data Supplement).
DISCUSSION
Our work is based on analysis of data from a total of 2,582 patients
with cancer and reports two potentially practice-changing results.
First, we found that the BSA-adjusted CKD-EPI was the most
accurate and least biased published model to estimate GFR.
Second, we developed a new model that further improves the
estimation of GFR and allows calculation of predictive CIs for this
estimation. Both ﬁndings will help practicing oncologists who
prescribe platinum-based chemotherapy.
Determination of GFR is a cornerstone of the curative and
palliative management of patients with carboplatin-responsive
cancer such as lung, ovary, triple-negative– and germline
BRCA1/2 mutation–positive breast cancer, and seminomas.18-27
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Fig 3. Graphical illustrations of statistics used to compare the new model and published models. Box plots of the residuals (measured glomerular ﬁltration rate [GFR]
minus estimated GFR) for all published models and the new model using (A) the internal validation data set and (B) the external validation data set are shown. Notches
delineate an approximate 95% CI for the median residual, calculated as 6 1.58*interquartile range/n0.5. A positive or negative value for the median residual indicates
underestimation or overestimation bias, respectively. (C) Graphical illustration of GFR root-mean-squared error (RMSE) in the internal and external validation data sets. Error
bars describe the 95% CI on the basis of the x2 distribution for the calculated RMSE. (D) Graphical illustration of percentage of patients with a carboplatin dosing absolute
percentage error (APE) . 20% in the internal and external validation data sets. For all plots, blue represents the internal validation set and gold represents the external
validation data set. Adj, adjusted; CKD-EPI, chronic kidney disease epidemiology; MDRD, Modiﬁcation of Diet in Renal Disease.
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Carboplatin doses are most commonly calculated using the Calvert
equation,1 which is a linear relationship between GFR and dose.
GFR measurements or estimates therefore directly inﬂuence
dose accuracy. This is important because carboplatin is dose-
dependently linked to tumor response and toxicities.17 Methods
to measure GFR after tracer injection2 are laborious, expensive,
and not considered routine clinical investigations. Consequently,
oncologists often rely on methods to estimate GFR from bio-
metric patient data and routine blood test results, most notably
serum creatinine concentration. With the exception of the Wright
equation,8 which investigated 100 patients with cancer, these
methods have been developed for purposes other than chemo-
therapy dosing and with data from noncancer populations, which
are enriched for patients with impaired kidney function compared
with our data set.
Practice-changing clinical trials of carboplatin chemotherapy
have used gold standard 51Cr-EDTA GFR measurements,18-20
creatinine clearance using the Cockcroft-Gault model,21-23 the
Jelliffe model,24-27,42 or 24-hour urine creatinine collections.19 This
demonstrates absence of a consensus. The ﬁndings of our study
show that of the published methods, unadjusted CKD-EPI predicts
GFR (and consequently carboplatin doses) similarly well to the
Jelliffe, Wright, and Cockcroft-Gault models in patients with
cancer. We conﬁrmed the ﬁnding of other studies that the inclusion
of BSA in predictive models improves accuracy.12 BSA-adjusted
CKD-EPI had the lowest RMSE and bias, as well as the smallest
carboplatin dose APE. 20%, and should, therefore, be considered
the best published creatinine-based GFR estimation model.
Patients in the development group for the CKD-EPI model10
were noncancer patients and had a mean GFR of 68 mL/min/
1.73m2; thus they were different than the patient population in our
study (ie, the population of patients with cancer who were
scheduled to receive carboplatin or cisplatin chemotherapy). We
hypothesized that we could derive a new model to better predict
GFR for patients with cancer. We recognized that there are multiple
approaches to developing a model for the relationships among the
dependent variable, GFR, and the independent predicting vari-
ables. Square root–transformed GFR is an approximately normally
distributed variable, its relationship to the independent variables is
approximately linear, and the resulting residuals have a mean of
zero and constant variance. Therefore, we concluded that a linear
model with square-root transformation of GFR was appropriate.
Evidence from our internal and external validation work suggests
that our new model is the best currently available model to predict
GFR in patients with cancer.
From a clinical point of view, the most important advantage of
our newmodel is a reduction in the fraction of patients who receive
a carboplatin dose that is. 20% different from the dose calculated
using 51Cr-EDTA GFR, even when compared with the BSA-
adjusted CKD-EPI model. The absolute reduction in the exter-
nal validation set ranged from 34.23% for the Cockcroft-Gault and
18.92% for the BSA-adjusted CKD-EPI model to 11.71% with the
new model. In addition, we report the mean of the prediction as
well as the variance and, therefore, the predictive CI. This rep-
resents a further advantage because it will provide clinicians with
a gauge of the suitability of using the prediction in a given clinical
context. For example, our analysis demonstrated that only four of
58 patients from the validation data set with a measured GFR, 50
mL/min did not contain this value in the 95% predictive CI. We
present the data for the value 50 mL/min, but recognize that this
value would be dependent on the clinical context.30-32 We ac-
knowledge this fact by providing an estimated probability of the
patient’s true GFR being below a user-adjustable GFR value as part
of an online tool to offer a clinical guide for prescription of cis-
platin, which is a nephrotoxic chemotherapeutic.28,29
Further strengths of our study are the large data set from
patients with cancer, the stringent methodology, and the internal
and external validation of our ﬁndings. Our model is based on
standard biometric data and can be easily used in clinical practice.
The study is limited, however, by the white-only population, as
a result of the single-center population demographics. Others have
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Fig 4. Predictive CIs for glomerular ﬁltration rate (GFR) of each patient in the
internal validation data set. To obtain this ﬁgure, the new model ﬁtted on the
development data set was applied to all patients in the internal validation data set.
The measured GFR (gold points) and the estimated GFR (blue points) for each
patient are illustrated. Each horizontal line represents a 95% predictive CI for the
patient, with patients ordered in accession by their estimated GFR. The vertical
dashed line highlights the boundary at a GFR of 50 mL/min, below which cisplatin
administration would be considered with caution by most clinicians. Of the 494
patients in the internal validation data set, 24 (4.9%) had measured values outside
their prediction interval.
Table 2. Final Coefﬁcients for New Model
Variable Coefﬁcient Estimate Standard Error t Value P*
Intercept b0 1.813953 0.626 2.9 .004
Age b1 0.01914 0.010 1.83 .069
BSA b2 4.732776 0.355 13.34 , .001
ln(Cre) b3 23.71619 0.086 243.33 , .001
ln(Cre)2 b4 20.9142 0.117 27.83 , .001
ln(Cre)3 b5 1.062836 0.132 8.03 , .001
SexM b6 0.020197 0.174 0.12 .907
Age:SexM† b7 0.012465 0.003 4.31 , .001
Age:BSA† b8 20.0297 0.006 24.92 , .001
NOTE. The table describes the coefﬁcients ðbi ; i ¼ 0;…;8Þ of the ﬁnal model
(Eq 1) with the estimate value and standard deviation for each coefﬁcient. The
estimate for standard deviation of the residuals ðsÞwas 0.842 to four signiﬁcant
ﬁgures.
Abbreviations: BSA, body surface area; Cre, blood serum creatinine; SexM,
variable equals 1 if sex is male, 0 otherwise.
*From t test comparing coefﬁcient value to 0.
†X:Y indicates the interaction variable between variables X and Y.
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shown that adjustment factors improve GFR prediction for black
patients,6,10 and this should be a priority area for future in-
vestigations. The ﬁnal coefﬁcients reported in our study may be, to
a degree, center dependent as a result of center-dependent cre-
atinine results. This is a problem that has been addressed by in-
ternational guidelines to standardize creatinine reporting,43 which
are implemented at our center. Using creatinine as the main ex-
planatory variable in predicting GFR has its own limitations. Other
predicting variables (eg, cystatin C) have been used, but were not
available to us. Furthermore, their usefulness in patients with
cancer is uncertain, because their levels may ﬂuctuate in a cancer-
dependent and kidney function–independent manner.44 We also
did not analyze measurements of albumin, muscle mass, in-
formation on dietary and ﬂuid intake, and comorbidities such as
diabetes mellitus.
Our ﬁndings may be relevant for a broad range of clinical
decision making in patients with or without cancer diagnoses. GFR
inﬂuences clinical management in the context of drug dose ad-
justments45 and decision making in the context of clinical organ
support.41 Gold standard 51Cr-EDTA GFR measurement would
usually not be performed in these contexts. Future research should
also investigate if the new model can facilitate correlative and
ultimately causative analysis of toxicity and dose accuracy re-
lationships in clinical trials.
In conclusion, BSA-adjusted CKD-EPI is the most accurate
published model to estimate GFR in patients with cancer. Our new
model further improves the estimation accuracy for GFR and may
present a new standard of care and should be investigated alongside
BSA-adjusted CKD-EPI in clinical practice.
ONLINE TOOL
The new model has been implemented in an online tool.46 For any
given set of input data, the tool provides the eGFR according to the
new model, an estimated predictive CI for the true GFR (default
setting at 95%), an estimated probability of the true GFR be-
ing below or above an operator-chosen value (default setting at
50 mL/min), as well as the eGFR according to the BSA-adjusted
CKD-EPI model.
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